RT Journal Article
SR Electronic
T1 Establishment & lineage dynamics of the SARS-CoV-2 epidemic in the UK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.23.20218446
DO 10.1101/2020.10.23.20218446
A1 du Plessis, Louis
A1 McCrone, John T.
A1 Zarebski, Alexander E.
A1 Hill, Verity
A1 Ruis, Christopher
A1 Gutierrez, Bernardo
A1 Raghwani, Jayna
A1 Ashworth, Jordan
A1 Colquhoun, Rachel
A1 Connor, Thomas R.
A1 Faria, Nuno R.
A1 Jackson, Ben
A1 Loman, Nicholas J.
A1 O’Toole, Áine
A1 Nicholls, Samuel M.
A1 Parag, Kris V.
A1 Scher, Emily
A1 Vasylyeva, Tetyana I.
A1 Volz, Erik M.
A1 Watts, Alexander
A1 Bogoch, Isaac I.
A1 Khan, Kamran
A1 ,
A1 Aanensen, David M.
A1 Kraemer, Moritz U. G.
A1 Rambaut, Andrew
A1 Pybus, Oliver G.
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.23.20218446.abstract
AB The UK’s COVID-19 epidemic during early 2020 was one of world’s largest and unusually well represented by virus genomic sampling. Here we reveal the fine-scale genetic lineage structure of this epidemic through analysis of 50,887 SARS-CoV-2 genomes, including 26,181 from the UK sampled throughout the country’s first wave of infection. Using large-scale phylogenetic analyses, combined with epidemiological and travel data, we quantify the size, spatio-temporal origins and persistence of genetically-distinct UK transmission lineages. Rapid fluctuations in virus importation rates resulted in >1000 lineages; those introduced prior to national lockdown were larger and more dispersed. Lineage importation and regional lineage diversity declined after lockdown, whilst lineage elimination was size-dependent. We discuss the implications of our genetic perspective on transmission dynamics for COVID-19 epidemiology and control.Competing Interest StatementKK is the founder of BlueDot, a social enterprise that develops digital technologies for public health. AW and IIB received employment or consulting income from BlueDot during this research.Funding StatementCOG-UK is funded by the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. VH was supported by BBSRC grant BB/M010996/1; CR by a Fondation Botnar Research Award (Programme grant 6063) and UK Cystic Fibrosis Trust (Innovation Hub Award 001); JR by the UKRI GCRF One Health Poultry Hub (BB/S011269/1); MUGK by a Branco Weiss Fellowship and EU H2020 project MOOD; NRF by WT fellowship 204311/Z/16/Z and MRC-FAPESP awards MR/S0195/1 and 18/14389-0; TIV by a Branco Weiss Fellowship; IIB is funded by the Canadian Institutes for Health Research (02179 - 000); JTM, RMC, NJL and AR by WT Collaborators Award 206298/Z/17/Z; AR and ES by ERC grant 725422; DMA by NIHR Global Health Research Unit (16/136/111); OGP, MUGK, LDP and AEZ by the Oxford Martin School. AW and IIB received employment or consulting income from BlueDot during this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No such approval or exemption was necessary, as all data used are anonymised and publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK SARS-CoV-2 genomes and public metadata are available from www.cogconsortium.uk/data/ and deposited at gisaid.org and ENA (bioproject PRJEB37886). Non-UK genomes were obtained from gisaid.org. Raw data and analysis files for this work are in supplementary materials or available from GitHub at https://github.com/COG-UK/UK-lineage-dynamics-analysis, which also contains a list of sequence accession numbers. A GISAID acknowledgments table is available at https://github.com/COG-UK/UK-lineage-dynamics-analysis https://www.cogconsortium.uk/data/ https://gisaid.org https://github.com/COG-UK/UK-lineage-dynamics-analysis